Which medication is specifically indicated for excessive sedation during treatment?

Zulresso (brexanolone) is specifically indicated for the treatment of postpartum depression, and its use in treating excessive sedation is related to its dosage and administration in a controlled environment. It operates as a positive allosteric modulator of GABA-A receptors, which can affect sedation levels, making it relevant in managing patients who may experience excessive sedation as a side effect during treatment.

The other medications listed have different primary indications or effects that do not specifically target excessive sedation. Spravato (esketamine) is used for treatment-resistant depression, Abilify (aripiprazole) is primarily an antipsychotic that can stabilize mood, and amitriptyline is an antidepressant that, while it may have sedative effects, is not specifically indicated for managing excessive sedation. Thus, Zulresso stands out as the appropriate choice for addressing this particular concern.